Susan Garcia Castillo, MD
Endocrinology, Diabetes & Metabolism · Macon, GANPI 1912493669
Payments from drug & device makers
Across 237 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$718
- Sanofi-aventis U.S. LLC$366
- Novartis$360
- Amgen$299
- Radius Health, Inc.$289
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,197100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $1,038 |
| Lilly USA, LLC | 38 | $718 |
| Sanofi-aventis U.S. LLC | 17 | $366 |
| Novartis | 25 | $360 |
| Amgen | 18 | $299 |
| Radius Health, Inc. | 8 | $289 |
| Corcept Therapeutics | 9 | $211 |
| Bayer | 10 | $194 |
| Dexcom, Inc. | 5 | $179 |
| Kyowa Kirin, Inc. | 3 | $168 |
| AstraZeneca | 4 | $162 |
| Tandem Diabetes Care, Inc. | 8 | $158 |
| BETA Bionics, Inc. | 2 | $140 |
| Medtronic | 2 | $137 |
| Antares Pharma, Inc. | 4 | $84 |
| Amneal Pharmaceuticals LLC | 4 | $81 |
| IBSA Pharma Inc. | 4 | $74 |
| Madrigal Pharmaceuticals | 3 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Mannkind Corporation | 2 | $51 |
| Embecta Corp. | 2 | $47 |
| Sequel Med Tech, LLC | 2 | $45 |
| Boehringer Ingelheim | 3 | $43 |
| Halozyme Inc | 2 | $39 |
| Verity Pharmaceuticals Inc. | 2 | $39 |
| Merck | 1 | $29 |
| Amphastar Pharmaceuticals, Inc. | 1 | $22 |
| GSK | 1 | $21 |
| Tolmar, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Pfizer | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tymlos$124
- CRYSVITA$123
- MINIMED 780G$121
- DEXCOM G7 GSS (161)$114
- TEPEZZA$104
How this compares
$5,207 in reported general payments places this provider in the 60th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 314 | $532,512 |
| JardianceEmpagliflozin | 230 | $263,375 |
| MounjaroTirzepatide | 130 | $193,519 |
| Tresiba Flextouch U-200Insulin Degludec | 93 | $109,670 |
| TrulicityDulaglutide | 54 | $90,789 |
| FarxigaDapagliflozin Propanediol | 71 | $65,950 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $47,203 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $46,862 |
| RybelsusSemaglutide | 31 | $37,297 |
| TradjentaLinagliptin | 33 | $35,673 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $26,069 |
| JanuviaSitagliptin Phosphate | 28 | $24,664 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $23,781 |
| Novolog FlexpenInsulin Aspart | 75 | $23,749 |
| Humalog Kwikpen U-100Insulin Lispro | 76 | $22,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,038 | $586,772392 claims |
| Boehringer IngelheimJardiance, Tradjenta | $43 | $299,048263 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $718 | $289,420202 claims |
| AstraZenecaFarxiga | $162 | $65,95071 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $366 | $47,20331 claims |
| MerckJanuvia | $29 | $24,66428 claims |
| AbbVieSynthroid | $14 | $4,63986 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $81 | $1,843220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Macon
- Thomas JonesMacon$4.8M
- Ashwini GoreMacon$2.6M
- Barry JohnsMacon$495K
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.